The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...
FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for ...
The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 ...
The FDA has given accelerated approval to Bayer for oral HER2 tyrosine kinase inhibitor sevabertinib as a second-line treatment for advanced HER2-mutant non-small cell lung cancer (NSCLC), allowing it ...
A new oral HER2-directed breast cancer therapy from Bayer AG, and its companion diagnostic from Thermo Fisher Scientific Inc., have been approved by the U.S. FDA. Hyrnuo (sevabertinib), a reversible ...
FDA fast-tracks Bayer's Hyrnuo, unlocking a potential $800 million market and giving the stock another shot of life ...
Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved HYRNUO® (sevabertinib), an oral, reversible, tyrosine kinase inhibitor (TKI), for the treatment of adult patients ...
Bayer (BAYZF) stock is in focus as the FDA grants accelerated approval for the company's tumor drug Hyrnuo in non-squamous ...
Regeneron announced the FDA’s approval of two indications of Eylea HD, including an 8mg injection for patients with macular ...
Disney released the animated film’s full trailer Thursday ahead of its theatrical release March 6, 2026. Piper Curda, Bobby ...
The U.S. men’s national team starting lineup for the 2026 FIFA World Cup is taking shape after a successful November international window.
Bayer (BAYRY) announced that the FDA has approved Hyrnuo, an oral, reversible, tyrosine kinase inhibitor for the treatment of adult patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback